REGENERON PHARMACEUTICALS, INC. Operating Cash Flow
REGENERON PHARMACEUTICALS, INC. (REGN) reported Operating Cash Flow of $1.89 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $813.00M, a 28.96% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $1.08B, a 3.23% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $1.17B, a 7.29% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $1.62B, a 25.36% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $4.98B, a 12.63% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was $4.42B, a 3.78% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was $4.59B, a 8.39% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was $5.01B, a 29.18% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $813.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.89B 10-Q · filed 2026-07-30 | $3.06B derived: sum of 3 quarters · filed 2026-07-30 | $4.68B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $1.08B 10-Q · filed 2026-04-29 | $2.25B derived: sum of 2 quarters · filed 2026-04-29 | $3.87B derived: sum of 3 quarters · filed 2026-04-29 | $5.01B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.79B derived: sum of 2 quarters · filed 2026-02-04 | $3.93B derived: sum of 3 quarters · filed 2026-07-30 | $4.98B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $1.62B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.76B derived: sum of 2 quarters · filed 2026-07-30 | $3.81B 10-Q · filed 2025-10-28 | $5.07B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $1.14B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.19B 10-Q · filed 2026-07-30 | $3.45B derived: sum of 3 quarters · filed 2026-07-30 | $4.74B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $1.05B 10-Q · filed 2026-04-29 | $2.31B derived: sum of 2 quarters · filed 2026-04-29 | $3.60B derived: sum of 3 quarters · filed 2026-04-29 | $3.95B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.55B derived: sum of 2 quarters · filed 2026-02-04 | $2.91B derived: sum of 3 quarters · filed 2026-02-04 | $4.42B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $1.29B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.65B derived: sum of 2 quarters · filed 2025-10-28 | $3.16B 10-Q · filed 2025-10-28 | $4.25B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $354.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $1.87B 10-Q · filed 2025-08-01 | $2.96B derived: sum of 3 quarters · filed 2026-02-04 | $4.07B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $1.51B 10-Q · filed 2025-04-29 | $2.60B derived: sum of 2 quarters · filed 2026-02-04 | $3.72B derived: sum of 3 quarters · filed 2026-02-04 | $4.74B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $1.09B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.20B derived: sum of 2 quarters · filed 2026-02-04 | $3.23B derived: sum of 3 quarters · filed 2026-02-04 | $4.59B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $1.11B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.14B derived: sum of 2 quarters · filed 2024-10-31 | $3.50B 10-Q · filed 2024-10-31 | $5.22B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $1.02B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.39B 10-Q · filed 2024-08-01 | $4.11B derived: sum of 3 quarters · filed 2025-02-05 | $4.74B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $1.37B 10-Q · filed 2024-05-02 | $3.09B derived: sum of 2 quarters · filed 2025-02-05 | $3.72B derived: sum of 3 quarters · filed 2025-02-05 | $4.28B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $1.72B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $2.35B derived: sum of 2 quarters · filed 2025-02-05 | $2.91B derived: sum of 3 quarters · filed 2025-02-05 | $5.01B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $628.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.19B derived: sum of 2 quarters · filed 2023-11-02 | $3.29B 10-Q · filed 2023-11-02 | $5.67B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $564.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.67B 10-Q · filed 2023-08-03 | $5.04B derived: sum of 3 quarters · filed 2024-02-05 | $8.45B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $2.10B 10-Q · filed 2023-05-04 | $4.47B derived: sum of 2 quarters · filed 2024-02-05 | $7.89B derived: sum of 3 quarters · filed 2024-02-05 | $8.51B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $2.37B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $5.79B derived: sum of 2 quarters · filed 2024-02-05 | $6.41B derived: sum of 3 quarters · filed 2024-02-05 | $7.08B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $3.41B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.04B derived: sum of 2 quarters · filed 2022-11-03 | $4.71B 10-Q · filed 2022-11-03 | $5.94B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $626.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.30B 10-Q · filed 2022-08-03 | $2.53B derived: sum of 3 quarters · filed 2023-02-06 | $2.27B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $668.50M 10-Q · filed 2022-05-04 | $1.90B derived: sum of 2 quarters · filed 2023-02-06 | $1.65B derived: sum of 3 quarters · filed 2023-02-06 | $2.59B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $1.23B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $976.70M derived: sum of 2 quarters · filed 2023-02-06 | $1.92B derived: sum of 3 quarters · filed 2023-02-06 | $2.62B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | -$254.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $689.10M derived: sum of 2 quarters · filed 2021-11-04 | $1.39B 10-Q · filed 2021-11-04 | $2.17B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $943.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.64B 10-Q · filed 2021-08-05 | $2.43B derived: sum of 3 quarters · filed 2022-02-07 | $2.99B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $698.00M 10-Q · filed 2021-05-06 | $1.49B derived: sum of 2 quarters · filed 2022-02-07 | $2.04B derived: sum of 3 quarters · filed 2022-02-07 | $2.23B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $787.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $1.34B derived: sum of 2 quarters · filed 2022-02-07 | $1.53B derived: sum of 3 quarters · filed 2022-02-07 | $2.43B 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $557.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $745.60M derived: sum of 2 quarters · filed 2020-11-05 | $1.64B 10-Q · filed 2020-11-05 | $2.37B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $188.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.09B 10-Q · filed 2020-08-05 | $1.81B derived: sum of 3 quarters · filed 2021-02-08 | $2.27B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $897.00M 10-Q · filed 2020-05-05 | $1.63B derived: sum of 2 quarters · filed 2021-02-08 | $2.08B derived: sum of 3 quarters · filed 2021-02-08 | $2.47B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $728.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $1.18B derived: sum of 2 quarters · filed 2021-02-08 | $1.58B derived: sum of 3 quarters · filed 2021-02-08 | $2.20B 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $452.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $847.50M derived: sum of 2 quarters · filed 2019-11-05 | $1.47B 10-Q · filed 2019-11-05 | $1.47B 10-Q · filed 2018-11-06 | $2.03B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $394.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.01B 10-Q · filed 2019-08-06 | $1.01B 10-Q · filed 2018-08-02 | $1.58B derived: sum of 3 quarters · filed 2020-02-07 | $2.00B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $618.80M 10-Q · filed 2019-05-07 | $618.74M 10-Q · filed 2018-05-03 | $1.19B derived: sum of 2 quarters · filed 2020-02-07 | $1.60B derived: sum of 3 quarters · filed 2020-02-07 | $1.57B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $566.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $981.77M derived: sum of 2 quarters · filed 2020-02-07 | $951.20M derived: sum of 3 quarters · filed 2020-02-07 | $1.31B 10-K · filed 2020-02-07 | $1.31B 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $414.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $384.26M derived: sum of 2 quarters · filed 2018-11-06 | $740.16M 10-Q · filed 2018-11-06 | $1.13B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | -$30.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $325.33M 10-Q · filed 2018-08-02 | $715.71M derived: sum of 3 quarters · filed 2019-02-07 | $1.37B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $355.90M 10-Q · filed 2018-05-03 | $746.28M derived: sum of 2 quarters · filed 2019-02-07 | $1.40B derived: sum of 3 quarters · filed 2019-02-07 | $1.80B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $390.38M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $1.04B derived: sum of 2 quarters · filed 2019-02-07 | $1.44B derived: sum of 3 quarters · filed 2019-02-07 | $1.49B 10-K · filed 2019-02-07 | $1.47B 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $651.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.05B derived: sum of 2 quarters · filed 2017-11-08 | $1.10B 10-Q · filed 2017-11-08 | $1.38B derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $399.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $444.49M 10-Q · filed 2017-08-03 | $726.31M derived: sum of 3 quarters · filed 2018-02-08 | $1.62B derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $44.99M 10-Q · filed 2017-05-04 | $29.34M 10-Q · filed 2016-05-05 | $326.81M derived: sum of 2 quarters · filed 2018-02-08 | $1.22B derived: sum of 3 quarters · filed 2018-02-08 | $1.48B derived: sum of 4 quarters · filed 2018-02-08 | |||
| 2015-12-31 | $281.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $1.17B derived: sum of 2 quarters · filed 2018-02-08 | $1.43B derived: sum of 3 quarters · filed 2018-02-08 | $1.33B 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $892.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $1.15B derived: sum of 2 quarters · filed 2016-11-04 | $1.05B 10-Q · filed 2016-11-04 | $1.25B derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $257.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $156.10M 10-Q · filed 2016-08-04 | $354.28M derived: sum of 3 quarters · filed 2017-02-09 | $518.60M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | -$101.73M 10-Q · filed 2016-05-05 | -$87.50M 10-Q · filed 2015-05-07 | $96.45M derived: sum of 2 quarters · filed 2017-02-09 | $260.77M derived: sum of 3 quarters · filed 2017-02-09 | $597.18M derived: sum of 4 quarters · filed 2017-02-09 | |||
| 2014-12-31 | $198.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $362.50M derived: sum of 2 quarters · filed 2017-02-09 | $698.91M derived: sum of 3 quarters · filed 2017-02-09 | $752.43M 10-K · filed 2017-02-09 | $743.16M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $164.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $500.73M derived: sum of 2 quarters · filed 2015-11-04 | $554.26M 10-Q · filed 2015-11-04 | $544.87M 10-Q · filed 2014-11-04 | $835.99M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | $336.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $389.94M 10-Q · filed 2015-08-04 | $381.32M 10-Q · filed 2014-08-05 | $671.67M derived: sum of 3 quarters · filed 2016-02-11 | $764.12M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $53.53M 10-Q · filed 2015-05-07 | $335.26M derived: sum of 2 quarters · filed 2016-02-11 | $427.71M derived: sum of 3 quarters · filed 2016-02-11 | $555.88M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $281.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $374.18M derived: sum of 2 quarters · filed 2016-02-11 | $502.35M derived: sum of 3 quarters · filed 2016-02-11 | $588.60M 10-K · filed 2016-02-11 | $583.65M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | $92.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $220.62M derived: sum of 2 quarters · filed 2014-11-04 | $306.87M 10-Q · filed 2014-11-04 | $400.05M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $128.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $214.41M 10-Q · filed 2014-08-05 | $307.60M derived: sum of 3 quarters · filed 2015-02-12 | $305.21M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $86.25M 10-Q · filed 2014-05-08 | $179.43M derived: sum of 2 quarters · filed 2015-02-12 | $177.05M derived: sum of 3 quarters · filed 2015-02-12 | $98.67M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $93.19M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $90.80M derived: sum of 2 quarters · filed 2015-02-12 | $12.43M derived: sum of 3 quarters · filed 2015-02-12 | -$74.61M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | -$2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$80.76M derived: sum of 2 quarters · filed 2013-11-05 | -$167.80M 10-Q · filed 2013-11-05 | -$218.12M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | -$78.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$165.42M 10-Q · filed 2013-08-06 | -$215.74M derived: sum of 3 quarters · filed 2014-02-13 | -$262.47M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | -$87.04M 10-Q · filed 2013-05-03 | -$137.36M derived: sum of 2 quarters · filed 2014-02-13 | -$184.09M derived: sum of 3 quarters · filed 2014-02-13 | -$218.14M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | -$50.32M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | -$97.05M derived: sum of 2 quarters · filed 2014-02-13 | -$131.10M derived: sum of 3 quarters · filed 2014-02-13 | -$141.68M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | -$46.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | -$80.78M derived: sum of 2 quarters · filed 2012-10-24 | -$91.36M 10-Q · filed 2012-10-24 | -$132.22M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | -$34.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$44.63M 10-Q · filed 2012-07-25 | -$85.48M derived: sum of 3 quarters · filed 2013-02-15 | $76.02M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | -$10.58M 10-Q · filed 2012-04-26 | -$51.43M derived: sum of 2 quarters · filed 2013-02-15 | $110.07M derived: sum of 3 quarters · filed 2013-02-15 | $98.22M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | -$40.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $120.65M derived: sum of 2 quarters · filed 2013-02-15 | $108.80M derived: sum of 3 quarters · filed 2013-02-15 | $99.22M 10-K · filed 2013-02-15 | $96.34M 10-K · filed 2011-02-17 | |||
| 2010-09-30 | $161.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $149.65M derived: sum of 2 quarters · filed 2011-10-27 | $140.07M 10-Q · filed 2011-10-27 | $138.04M 10-Q · filed 2010-10-28 | $95.96M derived: sum of 4 quarters · filed 2012-02-21 | |||
| 2010-06-30 | -$11.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$21.43M 10-Q · filed 2011-07-28 | -$22.63M 10-Q · filed 2010-07-28 | -$65.54M derived: sum of 3 quarters · filed 2012-02-21 | -$75.36M derived: sum of 4 quarters · filed 2012-02-21 | |||
| 2010-03-31 | -$9.58M 10-Q · filed 2011-05-03 | -$53.69M derived: sum of 2 quarters · filed 2012-02-21 | -$63.51M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | -$44.11M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | -$53.93M derived: sum of 2 quarters · filed 2012-02-21 | -$69.94M 10-K · filed 2012-02-21 | -$72.23M 10-K · filed 2011-02-17 | ||||
| 2009-09-30 | -$9.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | -$25.83M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | -$16.00M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | -$89.09M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |